Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $460

Guggenheim analyst Jason Cassorla has maintained a Buy rating on Elevance Health (NYSE: ELV) and raised the price target from $455 to $460. This adjustment reflects a positive outlook for the company's stock performance.